Advanced Technologies and Regenerative Medicine, LLC

Medos International Sarl

Depuy Mitek, Inc.

Johnson & Johnson Regenerative Therapeutics, LLC

Julius Lopez

Dongling Su

Julia Hwang

Venkata R Garigapati

Compositions and methods are provided for treating joint conditions, such as osteoarthritis and/or the pain associated therewith. The compositions and methods utilize a first component, namely hyaluronic acid ('HA'), in combination with a lyophilized second component that is effective to at least temporarily reduce the viscosity of the HA. In an exemplary embodiment, the second component is one or more glycosaminoglycans ('GAG'), such as chondroitin sulfate (&#x201c;CS&#x201d;), including CS4 and/or CS6, dermatan sulfate, heparin, heparan sulfate, and keratan sulfate. The composition can optionally include other joint supplements, such as glucosamine (&#x201c;GlcN&#x201d;).

Compositions and methods for treating joints

Compositions and methods are provided for treating joint conditions, such as osteoarthritis and/or the pain associated therewith. The compositions and methods utilize a first component, namely hyaluraonic acid ('HA'), in combination with a lyophilized second component that is effective to at least temporarily reduce the viscosity of the HA. In an exemplary embodiment, the second component is one or more glycosaminoglycans ('GAG'), such as chondroitin sulfate (&#x201c;CS&#x201d;), including CS4 and/or CS6, dermatan sulfate, heparin, heparan sulfate, and keratan sulfate. The composition can optionally include other joint supplements, such as glucosamine (&#x201c;GlcN&#x201d;).

Liquid formulations of bone morphogenetic proteins are provided for prolonged use at elevated temperatures. More specifically, the invention relates to liquid formulations comprising rhGDF-5, trehalose, and one or more biocompatible excipients that provide stability to the protein for at least 30 days at temperatures up to body temperature.

Protein formulations for use at elevated temperatures

Improved formulations and methods are provided for stabilizing a solution of bone morphogenetic protein. The compositions comprise an acetate buffered solution of GDF-5 and other excipients wherein the solution has a pH of from about 4.2 to about 5.3, thereby providing for a biologically isotonic solution having improved stability of the GDF-5 protein during storage, handling, and use.

Growing community of inventors

Dorchester, MA, United States of America

Julius Lopez